Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Wooil Kwon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4827-7805; OpenAlex author ID A5008890977, A5022449514, A5024933931, A5035117222, A5140398987, A5144018760, A5159632047. Sources: ClinicalTrials.gov.

Their work

Papers
99 (first author 8, last author 5)
Trials
1
Grants
0
Labs led
1
Collaborators
203
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 5 papers · 2019: 4 papers · 2020: 8 papers · 2021: 12 papers · 2022: 9 papers · 2023: 15 papers, 1 trial · 2024: 16 papers · 2025: 15 papers · 2026: 8 papers

Papers 50 of 99

  1. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. Co-author DOI 10.1016/j.ejca.2026.116903↗
  2. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  3. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Last author DOI 10.1016/j.suronc.2026.102368↗
  4. ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer. Co-author DOI 10.1038/s41388-026-03871-0↗
  5. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  6. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  7. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Co-author DOI 10.1245/s10434-026-20624-1↗
  8. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… Last author DOI 10.4174/astr.2026.111.2.93↗
  9. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Co-author DOI 10.1002/jhbp.12122↗
  10. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-11833-y↗
  11. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.04.001↗
  12. Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenoca… Co-author DOI 10.1038/s12276-024-01382-0↗
  13. SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. Co-author DOI 10.1038/s12276-025-01596-w↗
  14. The FOXP1-ABCG2 axis promotes the proliferation of cancer stem cells and induces chemoresistance in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00896-7↗
  15. SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-07476-5↗
  16. Machine learning models for pancreatic cancer diagnosis based on microbiome markers from serum extracellular vesicles. Co-author DOI 10.1038/s41598-025-94183-y↗
  17. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Co-author DOI 10.1186/s12935-025-03671-8↗
  18. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Co-author DOI 10.1245/s10434-024-16743-2↗
  19. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… First author DOI 10.1245/s10434-025-17389-4↗
  20. ASO Author Reflections: In the Era of Neoadjuvant Chemotherapy for Pancreatic Cancer, Should the Definition of Resection Margin Change or Stay the Same? First author DOI 10.1245/s10434-025-17460-0↗
  21. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  22. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. Co-author DOI 10.3390/nu17040647↗
  23. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… Co-author DOI 10.4174/astr.2025.109.2.61↗
  24. Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cac2.12585↗
  25. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Co-author DOI 10.1002/jhbp.12048↗
  26. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. First author DOI 10.1002/jhbp.12049↗
  27. Emerging role of local treatment in the era of advanced systemic treatment in pancreatic cancer with liver metastasis: A systematic review and meta-analysis. Co-author DOI 10.1002/jhbp.12051↗
  28. Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/jhbp.1352↗
  29. Response to "The role of adjuvant chemotherapy in management of stage I pancreatic ductal adenocarcinoma deserves independent high quality research". Co-author DOI 10.1002/jhbp.1405↗
  30. Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. Co-author DOI 10.1002/jso.27851↗
  31. Prospective Comparison of [18F]FDG and [18F]AIF-FAPI-74 PET/CT in the Evaluation of Potentially Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11307-024-01950-w↗
  32. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  33. Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant… Last author DOI 10.1016/j.hpb.2023.11.015↗
  34. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2024.100824↗
  35. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000001184↗
  36. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … Co-author DOI 10.1097/js9.0000000000002034↗
  37. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Co-author DOI 10.1186/s12885-024-12795-5↗
  38. In Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Ductal Adenocarcinoma, Which Response is the More Reliable Indicator for Prognosis, Radiologic or Biochem… Co-author DOI 10.1245/s10434-023-14532-x↗
  39. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/biomedicines13010062↗
  40. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  41. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels. Co-author DOI 10.1002/jhbp.1302↗
  42. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score… Co-author DOI 10.1002/jhbp.1313↗
  43. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  44. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  45. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer… Last author DOI 10.1007/s11605-023-05850-2↗
  46. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Co-author DOI 10.1038/s43018-022-00479-7↗
  47. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtype… Co-author DOI 10.1038/s43018-023-00581-4↗
  48. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. Co-author DOI 10.1093/bjs/znac393↗
  49. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  50. Whole exome sequencing and RNA sequencing analyses of PDAC samples Co-author DOI 10.21203/rs.3.pex-2062/v1↗

Trials 1

  1. NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Study director NCT05529940↗

Closest collaborators

The 25 strongest of 203 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 75 shared papers, 2013–2026 · strength 12.14
  2. Won‐Gun Yun · 33 shared papers, 2022–2026 · strength 7.73
  3. Hye‐Sol Jung · 30 shared papers, 2022–2026 · strength 6.89
  4. Hongbeom Kim · 36 shared papers, 2017–2026 · strength 4.45
  5. Mirang Lee · 18 shared papers, 2020–2025 · strength 3.47
  6. Yoon Soo Chae · 14 shared papers, 2024–2026 · strength 3.40
  7. Joon Seong Park · 14 shared papers, 2018–2026 · strength 3.14
  8. Go‐Won Choi · 9 shared papers, 2025–2026 · strength 2.33
  9. Taesung Park · 19 shared papers, 2016–2025 · strength 2.07
  10. Daechan Park · 12 shared papers, 2021–2026 · strength 1.87
  11. Jin‐Young Jang · 11 shared papers, 2016–2026 · strength 1.83
  12. Younsoo Seo · 7 shared papers, 2025–2026 · strength 1.82
  13. Sun‐Whe Kim · 20 shared papers, 2013–2022 · strength 1.78
  14. Jae Seung Kang · 15 shared papers, 2017–2023 · strength 1.75
  15. Michael D. Kluger · 9 shared papers, 2021–2024 · strength 1.66
  16. Alexander S. Thomas · 9 shared papers, 2021–2024 · strength 1.66
  17. Sang Hyub Lee · 9 shared papers, 2019–2026 · strength 1.61
  18. Yoonhyeong Byun · 14 shared papers, 2019–2023 · strength 1.61
  19. Ja‐Lok Ku · 11 shared papers, 2019–2026 · strength 1.58
  20. Seungyeoun Lee · 13 shared papers, 2017–2025 · strength 1.44
  21. Do‐Youn Oh · 10 shared papers, 2017–2026 · strength 1.30
  22. Woo Hyun Paik · 7 shared papers, 2019–2026 · strength 1.19
  23. Ji Kon Ryu · 8 shared papers, 2019–2024 · strength 1.14
  24. Eui Kyu Chie · 7 shared papers, 2018–2025 · strength 1.11
  25. Sangyeop Hyun · 8 shared papers, 2023–2024 · strength 1.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.